Characteristics of patients on study
Patient no. . | Dose . | Sex/age . | HLA . | Ethnicity . | Stage . | Previous treatment . |
|---|---|---|---|---|---|---|
| Treated in remission | ||||||
| 729 | 2 × 107/m2 × 2 | M/50 | A2/11 | Asian | IV | RT, cisplatin, 5-FU |
| B56/61 | ||||||
| 606 | 2 × 107/m2 × 2 | F/59 | A2/2 | White | IV | RT, cisplatin, 5-FU |
| B60/61 | ||||||
| 697 | 2 × 107/m2 × 2 | F/11 | A1/2 | African | III | RT, cisplatin, MTX, 5-FU |
| B37/44 | American | |||||
| 815 | 1 × 108/m2 × 1, | M/19 | A33/36 | African | IV | RT, cisplatin, MTX, 5-FU |
| 2 × 108/m2 × 1 | B53/72 | American | ||||
| Treated with relapsed or refractory disease | ||||||
| 845 | 2 × 107/m2 × 1 | M/11 | A3/68 | White | IV | RT, cisplatin, MTX, 5-FU, paclitaxel, carboplatin, VP16, vinorelbine, gemcitabine |
| B7/35 | ||||||
| 894 | 2 × 107/m2 × 1, | M/36 | A1/32 | White | III | RT, cisplatin, 5-FU, carboplatin, ifosphamide, paclitaxel, radioactive seed implants, gemcitabine |
| 1 × 108/m2 × 1 | B27/35 | |||||
| 389 | 2 × 107/m2 × 1, | F/17 | A2/3 | White | IV | RT, cisplatin, MTX, 5-FU, carboplatin, paclitaxel |
| 1 × 108/m2 × 1* | B44 | |||||
| 918 | 2 × 107/m2 × 1, | M/16 | A11/68 | Hispanic | IV | RT, cisplatin, MTX, 5-FU |
| 1 × 108/m2 × 1 | B49/52 | |||||
| 1042 | 1 × 108/m2 × 1, | F/46 | A2/24 | Asian | IV | RT, cisplatin, 5-FU, docetaxel, CPT-11 |
| 2 × 108/m2 × 1 | B51/61 | |||||
| 1046 | 1 × 108/m2 × 1, | M/16 | A30/68 | African | IV | RT, cisplatin, MTX, 5-FU, docetaxel, oxaliplatin, epirubicin, gemcitabine, etoposide |
| 2 × 108/m2 × 1 | B18/42 | American |
Patient no. . | Dose . | Sex/age . | HLA . | Ethnicity . | Stage . | Previous treatment . |
|---|---|---|---|---|---|---|
| Treated in remission | ||||||
| 729 | 2 × 107/m2 × 2 | M/50 | A2/11 | Asian | IV | RT, cisplatin, 5-FU |
| B56/61 | ||||||
| 606 | 2 × 107/m2 × 2 | F/59 | A2/2 | White | IV | RT, cisplatin, 5-FU |
| B60/61 | ||||||
| 697 | 2 × 107/m2 × 2 | F/11 | A1/2 | African | III | RT, cisplatin, MTX, 5-FU |
| B37/44 | American | |||||
| 815 | 1 × 108/m2 × 1, | M/19 | A33/36 | African | IV | RT, cisplatin, MTX, 5-FU |
| 2 × 108/m2 × 1 | B53/72 | American | ||||
| Treated with relapsed or refractory disease | ||||||
| 845 | 2 × 107/m2 × 1 | M/11 | A3/68 | White | IV | RT, cisplatin, MTX, 5-FU, paclitaxel, carboplatin, VP16, vinorelbine, gemcitabine |
| B7/35 | ||||||
| 894 | 2 × 107/m2 × 1, | M/36 | A1/32 | White | III | RT, cisplatin, 5-FU, carboplatin, ifosphamide, paclitaxel, radioactive seed implants, gemcitabine |
| 1 × 108/m2 × 1 | B27/35 | |||||
| 389 | 2 × 107/m2 × 1, | F/17 | A2/3 | White | IV | RT, cisplatin, MTX, 5-FU, carboplatin, paclitaxel |
| 1 × 108/m2 × 1* | B44 | |||||
| 918 | 2 × 107/m2 × 1, | M/16 | A11/68 | Hispanic | IV | RT, cisplatin, MTX, 5-FU |
| 1 × 108/m2 × 1 | B49/52 | |||||
| 1042 | 1 × 108/m2 × 1, | F/46 | A2/24 | Asian | IV | RT, cisplatin, 5-FU, docetaxel, CPT-11 |
| 2 × 108/m2 × 1 | B51/61 | |||||
| 1046 | 1 × 108/m2 × 1, | M/16 | A30/68 | African | IV | RT, cisplatin, MTX, 5-FU, docetaxel, oxaliplatin, epirubicin, gemcitabine, etoposide |
| 2 × 108/m2 × 1 | B18/42 | American |
M indicates male; RT, radiotherapy; 5-FU, 5-fluoruracil; F, female; and MTX, methotrexate.
Stage according to American Joint Committee for Cancer Staging and End-Results Reporting staging system 1997.23
VP16 indicates etoposide; CTP-11 is irinotecan.
This patients received additional doses of 1 × 108 CTLs/m2 at 6 months, 9 months, and 12 months after the initial CTL infusions.